TAZAROTENE Drug Patent Profile
✉ Email this page to a colleague
When do Tazarotene patents expire, and when can generic versions of Tazarotene launch?
Tazarotene is a drug marketed by Cosette, Fougera Pharms Inc, Taro, Padagis Israel, and Solaris Pharma Corp. and is included in seven NDAs.
The generic ingredient in TAZAROTENE is tazarotene. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tazarotene
A generic version of TAZAROTENE was approved as tazarotene by TARO on April 3rd, 2017.
Summary for TAZAROTENE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 129 |
Clinical Trials: | 52 |
Patent Applications: | 4,422 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TAZAROTENE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TAZAROTENE |
What excipients (inactive ingredients) are in TAZAROTENE? | TAZAROTENE excipients list |
DailyMed Link: | TAZAROTENE at DailyMed |
Recent Clinical Trials for TAZAROTENE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ortho Dermatologics | Phase 4 |
Dermatology Consulting Services, PLLC | Phase 4 |
Zagazig University | Phase 2 |
Pharmacology for TAZAROTENE
Drug Class | Retinoid |
Anatomical Therapeutic Chemical (ATC) Classes for TAZAROTENE
Paragraph IV (Patent) Challenges for TAZAROTENE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ARAZLO | Topical Lotion | tazarotene | 0.045% | 211882 | 1 | 2022-05-12 |
US Patents and Regulatory Information for TAZAROTENE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cosette | TAZAROTENE | tazarotene | CREAM;TOPICAL | 208662-001 | Dec 22, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Padagis Israel | TAZAROTENE | tazarotene | GEL;TOPICAL | 213079-002 | Apr 25, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cosette | TAZAROTENE | tazarotene | GEL;TOPICAL | 215433-001 | Sep 13, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Solaris Pharma Corp | TAZAROTENE | tazarotene | GEL;TOPICAL | 213644-001 | Mar 20, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |